GeneDx Holdings Corp. (WGS) Q2 Earnings and Revenues Beat Estimates

Financial Performance - GeneDx Holdings Corp. reported quarterly earnings of $0.5 per share, exceeding the Zacks Consensus Estimate of $0.1 per share, and compared to a loss of $0.11 per share a year ago, representing an earnings surprise of +400.00% [1] - The company posted revenues of $102.69 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 21.24%, and compared to year-ago revenues of $70.51 million [2] Stock Performance - GeneDx Holdings shares have increased approximately 10.5% since the beginning of the year, outperforming the S&P 500's gain of 8.6% [3] - The current consensus EPS estimate for the upcoming quarter is $0.30 on revenues of $93.15 million, and for the current fiscal year, it is $1.13 on revenues of $371.3 million [7] Industry Outlook - The Medical Services industry, to which GeneDx Holdings belongs, is currently ranked in the top 37% of over 250 Zacks industries, indicating a favorable outlook [8] - The company has consistently surpassed consensus EPS estimates over the last four quarters, indicating strong performance within its industry [2]